Biologics Bone Therapeutics to strategically focus on lead cell therapy product ALLOB byChris StewartMarch 29, 2022
Biologics Extremities Financial Spine Top Stories Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB byChris StewartNovember 29, 2021
Biologics Extremities Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study byChris StewartJanuary 13, 2021
Biologics Spine Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion byChris StewartOctober 14, 2020
Biologics Extremities Financial Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia byJosh SandbergOctober 5, 2020
Biologics Spine Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure byJosh SandbergJune 13, 2019
Biologics Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study byJosh SandbergSeptember 14, 2018
Biologics Bone Therapeutics SA : Announces all Patients Meet Primary Endpoint in ALLOB® Phase I/IIA Delayed-Union Study Interim Analysis byJosh SandbergSeptember 20, 2017
Hospitals Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial byJosh SandbergMay 18, 2016
Spine Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study byJosh SandbergMay 5, 2016
